Highland Capital Management 13F: Cuts LLY Stake by $3M

On October 26, 2026, Highland Capital Management cut its position in Eli Lilly and Company (LLY) by 2,558 shares, bringing its total to 8,373 shares valued at approximately $9.7 million. This information comes from the fund's latest Form 13F filing with the SEC.

Highland's cut represents a 23.4% decrease in its Eli Lilly holdings, which now account for 1.16% of the fund's total reported value of $833.1 million. The fund ranks 13th among the 415 positions it holds.

LLY Eli Lilly and Company

$1,279.14 ▲ +18.97% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Other Institutional Activity in Eli Lilly

Ascent Wealth Partners holds 9,135 shares of Eli Lilly, having increased its stake by 9,135 shares. Evergreen Capital Management also raised its position, adding 1,878 shares for a total of 14,030 shares. Additionally, Signaturefd increased its stake by 961 shares, bringing its total to 27,035 shares.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly shares recently traded around $1,279.16, which is about equal to the $1,279.14 close on the filing date. The stock is currently above its 50-day moving average by 7.6% and its 200-day moving average by 17.8%. However, it is about 3.2% below its 52-week high of $1,321.21.

Recent Earnings

Eli Lilly reported trailing twelve-month revenue of approximately $79.7 billion and an EPS of $29.79. The company's next earnings report is scheduled for October 29, 2026.

Dividend

Eli Lilly has an annual dividend rate of $6.92, which gives it a yield of 0.54%.

Insider Buying and Selling at Eli Lilly and Company

Several insiders sold shares earlier this year, including General Counsel Anat Hakim, who sold 5,000 shares at an average price of $1,190 on August 7, 2026, totaling about $5.95 million. Officer Donald A. Zakrowski sold 2,000 shares for $2.37 million on August 10, 2026. Officer Patrik Jonsson sold 6,500 shares for approximately $7.64 million on August 17, 2026.

Analysts Set New Price Targets

On September 28, 2026, JP Morgan maintained an Overweight rating on Eli Lilly with a price target of $1,500. Morgan Stanley also maintained an Overweight rating with a target of $1,430 on October 7, 2026. The consensus recommendation for Eli Lilly remains a buy with a mean target price of $1,333.72.

About Eli Lilly

Eli Lilly and Company discovers, develops, manufactures, and markets a range of pharmaceutical products. The company is based in Indianapolis, IN, and serves markets in the United States, Europe, China, Japan, and globally.

Bottom Line

Investors should watch for Eli Lilly's upcoming earnings report on October 29, 2026, as well as any further filings from Highland Capital Management regarding its position in the company.